Idenix Pharmaceuticals, Inc.

Corporate Headquarters
60 Hampshire Street
Cambridge
Massachusetts
02139
United States

Tel: 617-995-9800
Fax: 617-995-9801

Show articles for this employer

About Idenix Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

Currently, there are no jobs for this employer on BioSpace.

Browse jobs with BioSpace Featured Employers here.